


**Product Name** : IPI-549  
**Cat. No.** : PC-42233  
**CAS No.** : 1693758-51-8  
**Molecular Formula** : C<sub>30</sub>H<sub>24</sub>N<sub>8</sub>O<sub>2</sub>  
**Molecular Weight** : 528.564  
**Target** : PI3K  
**Solubility** : DMSO: 15 mg/mL



## Biological Activity

Eganelisib (IPI-549) is a potent, highly selective, orally active inhibitor of **PI3K $\gamma$**  with IC<sub>50</sub> of 16 nM, displays >100-fold selectivity over other lipid and protein kinases (PI3K $\alpha$  IC<sub>50</sub>=3.2  $\mu$ M, PI3K $\beta$  IC<sub>50</sub>=3.5  $\mu$ M, PI3K $\delta$  IC<sub>50</sub>>8.4  $\mu$ M).

Eganelisib (IPI-549) demonstrates excellent PI3K $\gamma$  potency (IC<sub>50</sub>=1.2 nM) and selectivity against other Class I PI3K isoforms (>146-fold) in cellular phospho-AKT assays, dose dependently inhibits PI3K $\gamma$  dependent bone marrow-derived macrophage (BMDM) migration.

Eganelisib (IPI-549) demonstrates favorable pharmacokinetic properties and robust inhibition of PI3K- $\gamma$  mediated neutrophil migration in vivo.

## References

Evans CA, et al. *ACS Med Chem Lett.* 2016 Jul 22;7(9):862-7.

De Henau O, et al. *Nature.* 2016 Nov 17;539(7629):443-447.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com